- Home
- GMTL vs VSTM Comparison
GMTL vs VSTM Comparison
Compare GMTL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMTL | VSTM |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.4M | 395.4M |
| IPO Year | 2024 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GMTL | VSTM |
|---|---|---|
| Price | $13.54 | $7.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $30.00 | $16.50 |
| AVG Volume (30 Days) | 187.6K | ★ 1.9M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $8.60 | $3.43 |
| 52 Week High | $22.21 | $11.25 |
Technical Indicators
Market Signals| Indicator | GMTL | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 66.41 |
| Support Level | $12.35 | $6.68 |
| Resistance Level | $13.82 | $7.86 |
| Average True Range (ATR) | 0.94 | 0.45 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 82.28 | 70.07 |
Price Performance
Historical ComparisonAbout GMTL Guardian Metal Resources PLC ADS
Guardian Metal Resources PLC focuses on metals exploration and development, with a focus on precious metals exploration in North America. The Company has one business segment, which is the exploration and evaluation of mineral resources in Nevada, USA. Its exploration projects comprise the Pilot Mountain Project, Tempiute Project, Golconda Summit Project, Stonewall Project, and Garfield Project, and the Group is the operator of the Golconda Summit Project.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.